切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2018, Vol. 07 ›› Issue (01) : 77 -81. doi: 10.3877/cma.j.issn.2095-3232.2018.01.019

所属专题： 文献；

基础研究

耐药基因蛋白和Ki67在原发性肝癌中的表达及其在预后中的价值
郭飞宇1, 杨军1, 熊书名1, 高森1, 朱茂群1, 李建平1,†()   
  1. 1. 214000　江苏省无锡市，南通大学第三附属医院肝胆外科
  • 收稿日期:2017-11-17 出版日期:2018-02-10
  • 通信作者: 李建平
  • 基金资助:
    无锡市医院管理中心科研项目(YGZXZ1402)

Expressions of drug resistance gene proteins and Ki67 in primary liver cancer and their value in prognosis

Feiyu Guo1, Jun Yang1, Shuming Xiong1, Sen Gao1, Maoqun Zhu1, Jianping Li1,†()   

  1. 1. Department of Hepatobiliary Surgery, the Third Affiliated Hospital of Nantong University, Wuxi 214000, China
  • Received:2017-11-17 Published:2018-02-10
  • Corresponding author: Jianping Li
  • About author:
    Corresponding author: Li Jianping, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

郭飞宇, 杨军, 熊书名, 高森, 朱茂群, 李建平. 耐药基因蛋白和Ki67在原发性肝癌中的表达及其在预后中的价值[J]. 中华肝脏外科手术学电子杂志, 2018, 07(01): 77-81.

Feiyu Guo, Jun Yang, Shuming Xiong, Sen Gao, Maoqun Zhu, Jianping Li. Expressions of drug resistance gene proteins and Ki67 in primary liver cancer and their value in prognosis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2018, 07(01): 77-81.

目的

探讨P-糖蛋白（Pgp）、胎盘型谷胱甘肽-S-转移酶（GST-π）、拓扑异构酶Ⅱ（TopoⅡ）和胸苷酸合酶（TS）4种耐药基因蛋白及Ki67在原发性肝癌（肝癌）中的表达及其在预后中的价值。

方法

标本来源于2008年3月至2016年12月在南通大学第三附属医院接受诊治的41例肝癌患者。患者均签署知情同意书，符合医学伦理学规定。其中男26例，女15例；平均年龄（56±10）岁。采用免疫组化法检测肝癌组织中Pgp、GST-π、TopoⅡ、TS和Ki67的表达水平。相关性分析采用Spearman相关分析，生存率分析采用Kaplan-Meier法和Log-rank检验，患者的预后影响因素采用Cox比例风险回归模型分析。

结果

Pgp、GST-π、TopoⅡ、TS和Ki67在肝癌组织中存在阳性表达，阳性率分别为73%（30/41）、7%（3/41）、61%（25/41）、39%（16/41）和51%（21/41）。TS表达与Pgp、TopoⅡ表达呈正相关（rs=0.484，0.333；P<0.05）。生存分析结果显示TS和Ki67阳性患者和阴性患者生存情况差异有统计学意义（χ2=4.695，5.784；P<0.05）。Cox多因素回归分析显示TS和Ki67为影响患者总体预后的独立危险因素（HR=3.007，17.108；P<0.05）。

结论

Pgp、GST-π、TopoⅡ、TS在肝癌中均有表达，且TS和Pgp、TopoⅡ的表达呈正相关，TS和Ki67是影响患者预后的独立危险因素。

关键词: 多药耐药相关蛋白质类, P-糖蛋白, 谷胱甘肽S-转移酶pi, DNA拓扑异构酶类, 胸苷酸合酶, 肝肿瘤, 预后, 危险因素
Objective

To investigate the expressions of 4 drug resistance gene proteins P-glycoprotein (Pgp), Glutathionine-S-Transferase π (GST-π), topoisomerase Ⅱ (TopoⅡ) and thymidylate synthase (TS) and Ki67 in primary liver cancer (PLC) and their value in the prognosis of patients.

Methods

Samples were collected from 41 patients with PLC in the Third Affiliated Hospital of Nantong University between March 2008 and December 2016. The informed consents of all patients were obtained and the local ethical committee approval was received. There were 26 males and 15 females, with an average age of (56±10) years old. The expressions of Pgp, GST-π, Topo Ⅱ, TS and Ki67 in PLC tissues were detected by immunohistochemistry. Correlation analysis was conducted using Spearman correlation analysis. Survival rate was analyzed using Kaplan-Meier method and Log-rank test. Prognostic factors of these patients were analyzed by Cox proportional hazard regression model.

Results

Positive expressions of Pgp, GST-π, Topo Ⅱ, TS and Ki67 were detected in PLC tissues, and the positive expression rate was 73% (30/41), 7% (3/41), 61% (25/41), 39% (16/41) and 51% (21/41), respectively. The expression of TS was positively correlated with those of Pgp and Topo Ⅱ (rs=0.484, 0.333; P<0.05). Survival analysis showed that there were significant differences in the survival between TS, Ki67 positive and negative patients (χ2=4.695, 5.784; P<0.05). Cox multivariate regression analysis showed that TS and Ki67 were the independent risk factors for the overall prognosis (HR=3.007, 17.108; P<0.05).

Conclusions

Expressions of Pgp, GST-π, Topo Ⅱ and TS can be detected in PLC. The expression of TS is positively correlated with those of Pgp and Topo Ⅱ. TS and Ki67 are the independent risk factors for the prognosis of patients.

Key words: Multidrug resistance-associated proteins, P-Glycoprotein, Glutathione S-transferase pi, DNA topoisomerases, Thymidylate synthase, Liver neoplasms, Prognosis, Risk factors
图1 肝癌组织中Pgp、GST-π、TopoⅡ、TS和Ki67的表达（Envision法　×400）
表1 肝癌组织中Pgp、GST-π、TopoⅡ、TS和Ki67相关性分析结果
统计值 TS和Pgp TS和GST-π TS和TopoⅡ TS和Ki67
rs值 0.484 0.159 0.333 -0.054
P值 0.001 0.32 0.034 -0.737
图2 TS和Ki67对原发性肝癌患者生存情况影响的Kaplan-Meier生存曲线
表2 Pgp、GST-π、TopoⅡ、TS和Ki67对影响原发性肝癌患者总体预后的单因素和多因素分析
参数 单因素分析 多因素分析
HR 95％CI P值 HR 95％CI P值
PgP 1.639 0.941～2.853 0.081 ? ? ?
GST-π 1.325 0.723～2.427 0.362 ? ? ?
TopoⅡ 1.943 1.026～3.678 0.041 1.143 0.428～3.054 0.789
TS 1.883 -1.056～-3.358 0.032 3.007 1.501～6.022 0.002
Ki67 5.890 -1.177～29.482 0.031 17.108 ０2.576～113.608 0.003
[1]
Zhu RX, Seto WK, Lai CL, et al. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region[J]. Gut Liver, 2016, 10(3):332-339.
[2]
Tsurusaki M, Murakami T. Surgical and locoregional therapy of HCC: TACE[J]. Liver Cancer, 2015, 4(3):165-175.
[3]
Le Grazie M, Biagini MR, Tarocchi M, et al. Chemotherapy for hepatocellular carcinoma: the present and the future[J]. World J Hepatol, 2017, 9(21):907-920.
[4]
Li W, Song M. Expression of multidrug resistance proteins in invasive ductal carcinoma of the breast[J]. Oncol Lett, 2014, 8(5):2103-2109.
[5]
Chen JS, Wu BB, Bao HL, et al. Relationship between CIP2A expression, and prognosis and MDR-related proteins in patients with advanced gastric cancer[J]. Int J Clin Exp Pathol, 2015, 8(11):15007-15012.
[6]
Falato C, Lorent J, Tani E, et al. Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer[J]. Breast Cancer Res Treat, 2014, 147(2):407-414.
[7]
Liang SN, Huang YJ, Liu LL, et al. Study on the correlation between the expression of Ki67 and FasL and prognosis of cervical carcinoma[J]. Genet Mol Res, 2015, 14(3):8634-8639.
[8]
Ledwitch KV, Roberts AG. Cardiovascular ion channel inhibitor drug-drug interactions with P-glycoprotein[J]. AAPS J, 2017, 19(2):409-420.
[9]
张彩兰，刘斌，杨艳丽，等．多药耐药基因PgP、ToPo-Ⅱ、GST-π与Ki-67在肺癌中的表达及其临床病理学意义[J]．现代肿瘤医学，2013，21(1):81-84.
[10]
Tandia M, Mhiri A, Paule B, et al. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study[J]. Cancer Chemother Pharmacol, 2017, 79(4):759-766.
[11]
Marchewka Z, Piwowar A, Ruzik S, et al. Glutathione S- transferases class Pi and Mi and their significance in oncology[J]. Postepy Hig Med Dosw, 2017, 71(10):541-550.
[12]
Grassilli E, Narloch R, Federzoni E, et al. Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy[J]. Clin Cancer Res, 2013, 19(14):3820-3831.
[13]
林慧梅，安玉芳，张凡．多耐药基因在乳腺癌组织中的表达及价值[J]．河北医学，2015(10):1588-1590.
[14]
Kozuki T, Chikamori K, Surleac MD, et al. Roles of the C-terminal domains of topoisomerase Ⅱ α and topoisomeraseⅡβ in regulation of the decatenation checkpoint[J]. Nucleic Acids Res, 2017, 45(10):5995-6010.
[15]
Wei C, Pan Q, Wu K, et al. Clinical characterization for proliferation and metastasis in advanced hepatocellular carcinoma patients[J]. Int J Clin Exp Pathol, 2015, 8(10):13429-13431.
[16]
马静，魏素菊，王俊艳，等．BRCA1、TopoⅡα、Bcl-2在三阴乳腺癌中的表达及对预后的影响[J]．中国老年学杂志，2014，34(7):1811-1813.
[17]
李铁灵，郭海峰，李华洋．三阴性年轻乳腺癌患者BRCA1、TopoⅡα、Bcl-2表达和预后的关系[J]．现代肿瘤医学，2016(2):231-233.
[18]
肖秀丽，郭晶晶，龙汉安，等．四种耐药基因蛋白及Ki-67在浸润性乳腺癌组织中表达的临床意义[J]．泸州医学院学报．2012，35(3):277-281.
[19]
Al-Hajeili M, Shields AF, Hwang JJ, et al. Molecular testing to optimize and personalize decision making in the management of colorectal cancer[J]. Oncology, 2017, 31(4):301-312.
[20]
刘明东，余宗阳，赵忠全，等．PD-L1、Ki67预测非小细胞肺癌术后进展的研究[J]．现代肿瘤医学，2017，25(6):885-889.
[21]
赵文龙，吕立志，齐兴峰，等．肝细胞肝癌CD147和Ki67表达的相关性及其临床意义[J]．华南国防医学杂志，2016(11):700-704.
[1] 韩丹, 王婷, 肖欢, 朱丽容, 陈镜宇, 唐毅. 超声造影与增强CT对儿童肝脏良恶性病变诊断价值的对比分析[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 939-944.
[2] 刘欢颜, 华扬, 贾凌云, 赵新宇, 刘蓓蓓. 颈内动脉闭塞病变管腔结构和血流动力学特征分析[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 809-815.
[3] 马艳波, 华扬, 刘桂梅, 孟秀峰, 崔立平. 中青年人颈动脉粥样硬化病变的相关危险因素分析[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 822-826.
[4] 陈旭渊, 罗仕云, 李文忠, 李毅. 腺源性肛瘘经手术治疗后创面愈合困难的危险因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 82-85.
[5] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[6] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[7] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[8] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[9] 吴方园, 孙霞, 林昌锋, 张震生. HBV相关肝硬化合并急性上消化道出血的危险因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 45-47.
[10] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[11] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[12] 陆猛桂, 黄斌, 李秋林, 何媛梅. 蜂蛰伤患者发生多器官功能障碍综合征的危险因素分析[J]. 中华临床医师杂志(电子版), 2023, 17(9): 1010-1015.
[13] 王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[14] 李达, 张大涯, 陈润祥, 张晓冬, 黄士美, 陈晨, 曾凡, 陈世锔, 白飞虎. 海南省东方市幽门螺杆菌感染现状的调查与相关危险因素分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 858-864.
[15] 索利斌, 刘鲲鹏, 姚兰, 张华, 魏越, 王军, 陈骏, 苗成利, 罗成华. 原发性腹膜后副神经节瘤切除术麻醉管理的特点和分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 771-776.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号